z-logo
open-access-imgOpen Access
Dermal response to combined double filler administration
Author(s) -
Г. М. Могильная,
E.V. Fomicheva
Publication year - 2020
Publication title -
kubanskij naučnyj medicinskij vestnik
Language(s) - English
Resource type - Journals
eISSN - 2541-9544
pISSN - 1608-6228
DOI - 10.25207/1608-6228-2020-27-4-72-81
Subject(s) - hyaluronic acid , haematoxylin , extracellular matrix , medicine , masson's trichrome stain , vimentin , calcium , hyaluronidase , eosin , pathology , fibrosis , chemistry , staining , anatomy , biochemistry , immunohistochemistry , enzyme
Aim . This experimental work presents a comparative assessment of the effect of hyaluronic acid and crystalline calcium hydroxyapatite on derma in separate and combined application setting. Materials and methods . The study used rats (30 animals) for subdermal injection of 0.05 ml medium. Group 1 was administered calcium hydroxyapatite (Radiesse (Merz, Germany)), group 2 received hyaluronic acid (Restylane (SabQ, Sweden)) and Group 3 — both preparations combined in ratio 1:1 (Mix). Results were evaluated 4 months after the ller injection. Sections were stained with haematoxylin–eosin, van Gieson’s and Masson’s trichrome techniques. Collagen types I and III were detected with polyclonal antibodies (Abcam, England). Fibroblasts were positively identied with vimentin (LabVision), macrophages — with CD68 (LabVision) tagging. Effect of extracellular matrix remodelling was studied with α-SMA actin (Abcam, England). Results . We demonstrate that separate lling of hyaluronic acid and calcium hydroxyapatite produces different response mechanisms, while their combined administration does not lead to a marked voluming of the dermal extracellular matrix. Conclusion . Combined administration of the two llers under study may facilitate a prolonged effect of their combined action exceeding 4 months, due to the absence of brosis, complications and side effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here